{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156855,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Development Project of Suzhou","award":["Grant No.SKY2022134"],"award-info":[{"award-number":["Grant No.SKY2022134"]}]},{"name":"Targeted therapy and Modified Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia","award":["Grant No. H230094"],"award-info":[{"award-number":["Grant No. H230094"]}]},{"name":"Jiangsu Province Elderly Health Research Project","award":["Grant No. LKM2023015"],"award-info":[{"award-number":["Grant No. LKM2023015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06250-z","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:25:04Z","timestamp":1743841504000},"page":"1617-1622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML"],"prefix":"10.1007","volume":"104","author":[{"given":"Bao-Quan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Pei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-ying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"2","key":"6250_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","volume":"60","author":"J Yates","year":"1982","unstructured":"Yates J, Glidewell O, Wiernik P (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60(2):454\u2013462","journal-title":"Blood"},{"issue":"7","key":"6250_CR2","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","volume":"89","author":"IM Hann","year":"1997","unstructured":"Hann IM, Stevens RF, Goldstone AH (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council\u2019s 10th AML trial (MRC AML10). Adult and childhood leukemia working parties of the Medical Research Council. Blood 89(7):2311\u20132318","journal-title":"Blood"},{"issue":"7","key":"6250_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"DDN Courtney","year":"2020","unstructured":"Courtney DDN, Brian A, Jonas (2020) Vinod Pullarkat, et, al. Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"1","key":"6250_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"25","key":"6250_CR5","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"D Courtney","year":"2021","unstructured":"Courtney D, DiNardo,Curtis AL (2021) Koichi Takahashi, Venetoclax Combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768\u20132778","journal-title":"J Clin Oncol"},{"issue":"6","key":"6250_CR6","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"Huafeng","year":"2022","unstructured":"Huafeng, Wang (2022) Liping Mao,Min YangVenetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6):e415\u2013e424","journal-title":"Lancet Haematol"},{"issue":"7","key":"6250_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","volume":"14","author":"J Jin","year":"2013","unstructured":"Jin J, Wang J-X, Chen F-F (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 14(7):599\u2013608","journal-title":"Lancet Oncol"},{"issue":"8","key":"6250_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","volume":"10","author":"F Yuan","year":"2022","unstructured":"Yuan F, Li D, Li G (2022) Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. Ann Transl Med 10(8):490. 10.21037","journal-title":"Ann Transl Med"},{"key":"6250_CR9","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"J Yuanfei Shi","year":"2021","unstructured":"Yuanfei Shi J, Ye Y, Yang (2021) The Basic Research of the combinatorial therapy of ABT-199 and homoharringtonine on Acute myeloid leukemia. Front Oncol 11:692497. 10.3389","journal-title":"Front Oncol"},{"issue":"25","key":"6250_CR10","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K (2021) Et, al. Venetoclax Combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768\u20132778","journal-title":"J Clin Oncol"},{"issue":"8","key":"6250_CR11","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552\u2013e561","journal-title":"Lancet Haematol"},{"issue":"6","key":"6250_CR12","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"L Huafeng Wang","year":"2022","unstructured":"Huafeng Wang L, Mao M, Yang (2022) Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6):e415\u2013e424","journal-title":"Lancet Haematol"},{"key":"6250_CR13","doi-asserted-by":"crossref","unstructured":"Xie J, Bao X, Xue S-L (2023) et, al. Venetoclax with Decitabine as Frontline Treatment for Younger Adults with Newly Diagnosed ELN Adverse-Risk AML. Blood,;blood.2023020102. 10.1182","DOI":"10.2139\/ssrn.4342779"},{"issue":"8","key":"6250_CR14","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.leu.2404287","volume":"20","author":"J Jin","year":"2006","unstructured":"Jin J, Jiang D-Z, Mai W-Y (2006) Et, al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20(8):1361\u20131367","journal-title":"Leukemia"},{"issue":"7","key":"6250_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","volume":"14","author":"J 15 Jin","year":"2013","unstructured":"15 Jin J, Wang J-X, Chen F-F et al (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 14(7):599\u2013608","journal-title":"Lancet Oncol"},{"issue":"1","key":"6250_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2019.234880","volume":"105","author":"K Stefan","year":"2020","unstructured":"Stefan K, Bohlander (2020) A new kid on the block for acute myeloid leukemia treatment? Homoharringtonine interferes with key pathways in acute myeloid leukemia cells. Haematologica 105(1):7\u20139","journal-title":"Haematologica"},{"issue":"8","key":"6250_CR17","first-page":"617","volume":"42","author":"L Leukemia","year":"2021","unstructured":"Leukemia L, Group, Chinese Society of Hematology Chinese Medical Association (2021) Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL)(2021). Chin J Hematol August 2021 42(8):617\u2013623","journal-title":"Chin J Hematol August 2021"},{"issue":"6","key":"6250_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"P Christopher","year":"2022","unstructured":"Christopher P, Mill W, Fiskus, Courtney D, DiNardo (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood 139(6):907\u2013921","journal-title":"Blood"},{"issue":"1","key":"6250_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y (2023) Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: a Multicenter, phase 2 trial. J Hematol Oncol 16(1):42. 10.1186","journal-title":"J Hematol Oncol"},{"issue":"5","key":"6250_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/bjh.18788","volume":"201","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lv LZZ, Mao L et al (2023) Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukemia in routine clinical practice. Br J Haematol 201(5):995\u2013999","journal-title":"Br J Haematol"},{"issue":"5","key":"6250_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00277-023-05201-w","volume":"102","author":"Y Gando","year":"2023","unstructured":"Gando Y (2023) Takeo Yasu. Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia. Ann Hematol 102(5):1283\u20131285","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06250-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:10:43Z","timestamp":1745561443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06250-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6250"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06250-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5224506\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Committee of the First Affiliated Hospital of Soochow University (No. 026\/2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}